CJC-1295 + Ipamorelin Blend
A combined GHRH analog and ghrelin-receptor agonist preparation used in secretagogue research.
From$79.00Select size
Sermorelin
CAS90830-28-7
A GHRH(1-29) analog examined in endocrine and pituitary-signalling research.
- Test methods
- HPLC-UV + LC-MS
- Purity target
- 99%+ verified
- Sizes available
- 2
- Availability
- Backordered
Select size
Quantity
1
Total
$49.00
That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.
Certificate for this lot is pending. Every batch we ship is published at /coa before it goes out.
For Research Use Only. Not for Human Consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
✦ Research Notes
Background & literature
Origin
Sermorelin is the synthetic 1–29 amino acid fragment of human growth-hormone-releasing hormone — the shortest fragment of the 44-residue parent that retains full receptor activity, which is why it became the reference GHRH analog. It entered clinical research in the 1980s and was studied through the early 1990s, including in paediatric endocrinology, before being withdrawn from the US market in 2008 for commercial rather than safety reasons.
What has been characterised
Characterised as an agonist at the GHRH receptor on anterior pituitary somatotrophs, acting on the same receptor as endogenous GHRH but as a truncated 29-residue peptide. A 1990 study examined continuous subcutaneous GHRH(1–29)NH2 over a year in short, slowly growing children — historical clinical work on the parent molecule, and among the reasons sermorelin is the best-characterised member of this class. Not currently FDA-approved; GHRH analogs are on the WADA Prohibited List.
Sources
- 1.Clin Endocrinol (Oxf), 1990. PMID 2140733 — the founding clinical report on continuous subcutaneous GHRH(1-29)NH2 (title not reproduced here)
- 2.WADA Prohibited List — World Anti-Doping Agency
These notes are provided for scientific context only. They describe published laboratory and preclinical research and are not a claim of any effect in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Batch releases & restocks
Know when the next batch is tested
We publish an independent certificate for every lot before it ships. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.
Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.
Related Compounds
Ipamorelin
A selective ghrelin-receptor agonist studied in growth-hormone release research.
From$46.00Select size
HCG
A glycoprotein gonadotropin studied in receptor-binding and endocrine-signalling research models.
From$42.00Notify me
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.